Dec 3, 2024 8:00 am EST FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Nov 7, 2024 4:05 pm EST Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Sep 19, 2024 4:05 pm EDT Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
Sep 9, 2024 7:30 am EDT FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Aug 5, 2024 7:30 am EDT Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Jun 27, 2024 8:00 am EDT Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Jun 24, 2024 8:00 am EDT Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
